Navigation Links
ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH

PUNTA DEL ESTE, Uruguay--(BUSINESS WIRE)--Mar 23, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of data on ZIO-201 at the XXXI World Congress of the International Society of Hematology (ISH) meeting being held in Punta del Este, Uruguay. ZIO-201 is a proprietary form of the therapeutic active metabolite of ifosfamide (IFOS), a drug that is widely used in the treatment of lymphoma. However, IFOS can be problematic in treating lymphoma as certain IFOS metabolites cause debilitating bladder toxicity and confusion. Further, there is a variability in treatment effect associated with the metabolism of IFOS and resistance can develop. The Company believes that ZIO-201 could better deliver the clinical benefits of IFOS without the associated toxicities and the development of resistance.

Data presented at ISH yesterday highlighted that ZIO-201 was 10 to 30 fold more active than IFOS in most in vitro and in vivo models of lymphoma. ZIO-201 also killed IFOS-resistant lymphoma in cancer-bearing mice. In a phase I clinical study, there was little bone marrow toxicity and no hemorrhagic cystitis (bladder toxicity) or central nervous system (CNS) toxicity (confusion). The dose limiting toxicity was characterized by renal electrolyte imbalances. The maximum dose administered was equivalent to high-dose IFOS. Because of the modest bone marrow toxicity, ZIO-201 can be given to patients with bone marrow failure, an important distinction from IFOS in the treatment of patients with lymphoma. A phase II study of ZIO-201 in the treatment of lymphoma will begin later this year.

"These results with ZIO-201 are encouraging," commented Dr. Brian Schwartz, Chief Medical Officer at ZIOPHARM. "Avoiding the more serious toxicities associated with the administration of ifosfamide in addition to having the potential to treat resistant lymphoma patients with ZIO-201 could be an important step forward in r
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
4. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents ZIO Lymphoma Data ISH
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... April 16, 2007 /PRNewswire/ -- Sirion Therapeutics,Inc., ... has received orphan drug designation from the ... therapy,ganciclovir, for the treatment of acute herpetic ... Thea in Europe under,the brand name of ...
... at 2007 APA Meeting Also Showed No,Significant Impact ... 21, 2007 /PRNewswire-FirstCall/ --,Findings from two separate pooled ... on anxious symptoms and the,other on painful symptoms ... as a separate pooled analysis that examined the,effect ...
Cached Medicine Technology:Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... Option for the Treatment of ED-, INDIANAPOLIS, Jan. ... announced today that the U.S. Food and Drug Administration,(FDA) ... mg and,5 mg), an oral medication taken once per ... daily use is taken daily, men can attempt sexual,activity ...
... to Board of Directors, CINCINNATI, Jan. 8, ... PG ) today announced the appointment of Patricia ... Archer Daniels Midland,Corporation (NYSE: ADM ), to ... http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-a ), (Photo: http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-b ...
... Texas, Jan. 8 In 2006, 66% of Americans ... come from working in,seated sedentary jobs? Or do we ... or obese? No one knows for sure, but Texas ... to reverse this trend. Recently,Neutral Posture introduced the Ntune(TM) ...
... Big Rewards, CINCINNATI, Jan. 8 As part of ... be holding its Community Event,in all 2,435 Wal-Mart Supercenters across ... to teach, encourage and inspire women to take,control of their ... big rewards for their overall health and well-being., The ...
... 8 Bristol-Myers Squibb Company,(NYSE: BMY ... private equity firm,announced today that Avista has ... a business unit of Bristol-Myers Squibb. Bristol-,Myers ... of medical imaging,products for nuclear and ultrasound ...
... For twenty years, The Leukemia &,Lymphoma Society ... changed,lives, helped individuals achieve personal goals and most ... research., (See video from The Leukemia & ... diverse individuals, "Team In Training" helps,individuals prepare for ...
Cached Medicine News:Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Procter & Gamble Announces Appointment of Director 2Health News:Office Furniture That Helps Fight Fat! 2Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 2Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 3Health News:Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: